Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis : an open-label, 18-month, prospective, pilot study
| Errataetall: |
CommentIn: Ann Rheum Dis. 2021 Nov;80(11):e184. - PMID 31690621 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:78 |
|---|---|
| Enthalten in: |
Annals of the rheumatic diseases - 78(2019), 10 vom: 18. Okt., Seite 1444-1446 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nannini, Carlotta [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Monoclonal, Humanized |
|---|
| Anmerkungen: |
Date Completed 30.03.2020 Date Revised 13.11.2021 published: Print-Electronic CommentIn: Ann Rheum Dis. 2021 Nov;80(11):e184. - PMID 31690621 Citation Status MEDLINE |
|---|
| doi: |
10.1136/annrheumdis-2019-215585 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM298296942 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM298296942 | ||
| 003 | DE-627 | ||
| 005 | 20231225093842.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1136/annrheumdis-2019-215585 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0994.xml |
| 035 | |a (DE-627)NLM298296942 | ||
| 035 | |a (NLM)31213436 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nannini, Carlotta |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Remission maintenance after tocilizumab dose-tapering and interruption in patients with giant cell arteritis |b an open-label, 18-month, prospective, pilot study |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 30.03.2020 | ||
| 500 | |a Date Revised 13.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentIn: Ann Rheum Dis. 2021 Nov;80(11):e184. - PMID 31690621 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Clinical Trial | |
| 650 | 4 | |a Letter | |
| 650 | 4 | |a dmards (biologic) | |
| 650 | 4 | |a giant cell arteritis | |
| 650 | 4 | |a systemic vasculitis | |
| 650 | 4 | |a treatment | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a tocilizumab |2 NLM | |
| 650 | 7 | |a I031V2H011 |2 NLM | |
| 700 | 1 | |a Niccoli, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Sestini, Stelvio |e verfasserin |4 aut | |
| 700 | 1 | |a Laghai, Iashar |e verfasserin |4 aut | |
| 700 | 1 | |a Coppola, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Cantini, Fabrizio |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of the rheumatic diseases |d 1939 |g 78(2019), 10 vom: 18. Okt., Seite 1444-1446 |w (DE-627)NLM000174114 |x 1468-2060 |7 nnns |
| 773 | 1 | 8 | |g volume:78 |g year:2019 |g number:10 |g day:18 |g month:10 |g pages:1444-1446 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1136/annrheumdis-2019-215585 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 78 |j 2019 |e 10 |b 18 |c 10 |h 1444-1446 | ||